Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
The solution for a seamless quantitative bioanalysis
High selectivity is a critical element of successful quantitative bioanalysis. Recent...
Gene expression and miRNA data analysis
Automated analytical pipelines that are modular and flexible, combined with the use of...
[White Paper] Beyond LIMS: Redefining QC Digital Transformation
Discover how to modernise your QC workflow and...
